SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
View Top Employees from SemaThera Inc| Website | http://www.semathera.com |
| Revenue | $811000 |
| Employees | 6 (6 on RocketReach) |
| Founded | 2016 |
| Address | 227 Ave Westminster N, Montreal, Quebec H4X 1Z5, CA |
| Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Manufacturing General, Diabetic Macular Edema, Manufacturing, Science and Engineering, Other Healthcare Services, Ocular Diseases, Diabetes, Semaphorin 3A, Health Care, Therapeutics |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular SemaThera Inc employee's phone or email?
SemaThera Inc Questions
The SemaThera Inc annual revenue was $811000 in 2024.
Garth Cumberlidge is the President, Director and Chief Executive Officer of SemaThera Inc.
6 people are employed at SemaThera Inc.
SemaThera Inc is based in Montreal, Quebec.
The NAICS codes for SemaThera Inc are [32, 325, 32541, 3254].
The SIC codes for SemaThera Inc are [283, 28].
Top SemaThera Inc Employees
-
41
-
1
-
1
-
2
Related Companies
